Journal of Liver Cancer

Review Article

Update on Pathologic and Radiologic Diagnosis of Combined Hepatocellular-Cholangiocarcinoma: Hyungjin Rhee, Jae Hyon Park, Young Nyun Park; J Liver Cancer. 2021;21(1):12-24. Published online March 31, 2021; DOI: https://doi.org/10.17998/jlc.21.1.12

14,186 Views
394 Downloads
12 Citations

Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a malignant primary liver carcinoma characterized by the unequivocal presence of both hepatocytic and cholangiocytic differentiation within the same tumor. Recent research has highlighted that cHCC-CCAs are more heterogeneous than previously expected. In the updated consensus terminology and WHO 2019 classification, “classical type” and “subtypes with stem-cell features” of the WHO 2010 classification are no longer recommended. Instead, it is recommended that the presence and percentages of various histopathologic components and stem-cell features be mentioned in the pathologic report. The new terminology and classification enable the exchange of clearer and more objective information about cHCC-CCAs, facilitating multi-center and multinational research. However, there are limitations to the diagnosis of cHCC-CCA by imaging and biopsy. cHCC-CCAs showing typical imaging findings of HCC could be misdiagnosed as HCC and subjected to inappropriate treatment, if other clinical findings are not sufficiently considered. cHCC-CCAs showing at least one of the CCA-like imaging features or unusual clinical features should be subjected to biopsy. There may be a sampling error for the biopsy diagnosis of cHCC-CCA. An optimized diagnostic algorithm integrating clinical, radiological, and histopathologic information of biopsy is required to resolve these diagnostic pitfalls.

Citations

Citations to this article as recorded by

Combined hepatocellular-cholangiocarcinoma: a contemporary pathologic and molecular perspective
Taek Chung
Journal of Liver Cancer.2026; 26(1): 1. CrossRef
Imaging differentiation of hepatocellular carcinoma, combined hepatocellular-cholangiocarcinoma, and intrahepatic cholangiocarcinoma: pitfalls and advances
Jaeseung Shin, Taek Chung, Sang Yun Ha, Hyungjin Rhee
Journal of Liver Cancer.2026; 26(1): 9. CrossRef
Radiological Assessment of Liver and Biliary Neoplasms
Rayane El Rahi, Murat Yüce, Bachir Taouli
Hematology/Oncology Clinics of North America.2026; 40(4): 451. CrossRef
Advances in the imaging of liver cancer
Ijin Joo, Jeong Min Lee, Maxime Ronot
Journal of Hepatology.2026;[Epub] CrossRef
Preoperative Assessment of Bile Duct Cancer: The Role of Magnetic Resonance Imaging and Magnetic Resonance Cholangiopancreatography
Bohyun Kim
Investigative Magnetic Resonance Imaging.2026; 30(2): 75. CrossRef
Classification and early diagnostic markers of Primary hepatic carcinoma: a comprehensive review
Xinyao Liu, Lin Gong, Weiran Kong, Jie Kong, Yang Zhang, Chuantao Yuan, Shuai Chen
Biomarkers in Medicine.2026; 20(10): 649. CrossRef
Combined Hepatocellular-Cholangiocarcinoma: A Clinical and Molecular Review
Shaodian Xu, Julien Calderaro
Seminars in Liver Disease.2025; 45(04): 476. CrossRef
Enhancing liver cirrhosis varices and CSPH risk prediction with spleen stiffness measurement using 100-Hz probe
Jeong-Ju Yoo, Sun Ah Maeng, Young Chang, Sae Hwan Lee, Soung Won Jeong, Jae Young Jang, Gab Jin Cheon, Young Seok Kim, Hong Soo Kim, Sang Gyune Kim
Scientific Reports.2024;[Epub] CrossRef
MRI features of combined hepatocellular-cholangiocarcinoma
Noor Fatima Majeed, Mathew Macey, Marta Braschi Amirfarzan, Sheida Sharifi, Jeremy R Wortman
Abdominal Radiology.2024; 50(1): 169. CrossRef
Imaging findings of intrahepatic cholangiocarcinoma for prognosis prediction and treatment decision-making: a narrative review
Jun Gu Kang, Taek Chung, Dong Kyu Kim, Hyungjin Rhee
The Ewha Medical Journal.2024;[Epub] CrossRef
Differentiation between hepatic angiomyolipoma and hepatocellular carcinoma in individuals who are not at-risk for hepatocellular carcinoma
Sungtae Park, Myeong-Jin Kim, Kyunghwa Han, Jae Hyon Park, Dai Hoon Han, Young Nyun Park, Jaehyo Kim, Hyungjin Rhee
European Journal of Radiology.2023; 166: 110957. CrossRef
The Human TOR Signaling Regulator Is the Key Indicator of Liver Cancer Patients’ Overall Survival: TIPRL/LC3/CD133/CD44 as Potential Biomarkers for Early Liver Cancers
Soo Young Jun, Hyang Ran Yoon, Ji-Yong Yoon, Su-Jin Jeon, Jeong-Ju Lee, Debasish Halder, Jin-Man Kim, Nam-Soon Kim
Cancers.2021; 13(12): 2925. CrossRef

First
Prev
Page of 1
Next
Last

Search